SkinCeuticals Blemish Plus Age Defense: two US label eras and an unavailable page

The June 2026 record names Blemish Plus Age Defense, declares salicylic acid 1.5% as active and codes the form as gel. Its acne-treatment identity is the starting point here. The unavailable manufacturer page supplies no additional verified claims for this review; we do not treat a search description as the missing page. Newer US label. The reviewed item is consequently described as a US acne-label record, with that limitation in the directory scope as well as the body. This avoids suggesting that the unavailable regional marketing discussion was fully examined or that every product using a similar Blemish + Age name has the same declaration.

That boundary makes the review more exact, not more complete than its sources. The product-version guide explains why a regional sales account should not silently complete a different market’s posted label.

The December 2024 record uses NDC 49967-097 and codes lotion. The newer June 2026 record uses NDC 82046-558 and codes gel. These are differences between two posted US records, with their dates retained. They do not prove that every container changed at the same moment or establish the version on a reader’s shelf. Older lotion record. Newer gel record.

The Clean & Clear review provides another question about dated form and naming. It contributes a comparison route, not a formula history or evidence result for SkinCeuticals.

Both labels give salicylic acid 1.5% in the active field. Their inactive declarations separately name other entries, including Capryloyl Salicylic Acid. Those inactive names do not carry amounts in the examined lists. Reporting them as additional quantified active salicylic acid would change what the labels actually state. Earlier ingredients. Later ingredients. In particular, the presence of several acid names cannot be turned into a larger salicylic-acid active percentage. An inactive list identifies components without quantifying them. The separation is a reading of the posted fields, not a laboratory conclusion about how the entire formula behaves on skin.

No regional acid-blend percentage is added to these US fields. The two-percent comparison is useful for the broader principle: one stated active amount is not a calculation of every acid or a ranking of a whole formula.

The complete June 2026 inactive list includes Tocopherol and sunflower entries absent from the retained December 2024 list. That is a specific list comparison. It does not establish the amount of either ingredient, confirm a batch composition or demonstrate that the newer preparation gives a different clinical result. Complete older base. Complete newer base.

The La Roche-Posay review offers a separate example of examining dated ingredient fields. Across both reading questions, a posted addition can be named without turning it into a verified performance or supply finding.

The newer label’s use wording concerns reducing the number and severity of acne blemishes and pimples. That is the stated acne-use field, not a report of observed success in a supplied trial group. It does not independently verify a pore, aging or tone claim from an unreturned manufacturer page. Stated use. A use statement describes the purpose claimed for the product. It does not provide before-and-after observations, a participant count or a comparison with another item. Those additional evidence fields are still needed before the reviewer can discuss a specific measured outcome rather than the stated use.

The narrower label account is still useful. It identifies the purpose actually posted for this exact US product record. A full outcome method, participant denominator or comparator would be needed for a different kind of evidence claim; none is inferred from the product’s name.

The newer package information identifies a 30 mL gel. The label also retains drying and flammability cautions. These fields remain part of the record surrounding the active and use statements. The review does not turn them into handling instructions, a drying interval or an assurance about combining products. Package and caution fields.

A 30 mL quantity also does not establish how long a personal supply would last. The supply-term guide keeps quantity distinct from duration and fulfillment. Neither physical stock nor delivery was observed here.

FDA states that NDC assignment and directory inclusion do not establish FDA approval or verification of the submitted information. That framework is directly relevant to both US label identifiers. The labels are useful for comparing names, dates, active fields and complete bases; their existence is not a product-specific compliance audit. FDA listing limits. Newer identity fields.

The open record stays open: the unavailable US manufacturer text, a reader’s actual version and any complete performance study were not examined. The exact US label comparison can stand without borrowing a different market’s formula story to fill those spaces.